A Swedish population-based study of adverse birth outcomes among pregnant women treated with buprenorphine or methadone: Preliminary findings

Substance Abuse: Research and Treatment

Volumn 10, Issue , 2016, Pages 89-97

  Wurst, Keele E ^a,b   Zedler, Barbara K ^a   Joyce, Andrew R ^a   Sasinowski, Maciek ^a   Murrelle, E Lenn ^a  

^a Solveritas   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Buprenorphine; Methadone; Opioid agonist medication assisted treatment; Opioid dependence; Opioid use disorder; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; COHABITATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL AGE; NEONATAL ABSTINENCE SYNDROME; NEWBORN DEATH; OPIATE ADDICTION; POPULATION RESEARCH; PREGNANCY OUTCOME; PREMATURE LABOR; SMOKING; STILLBIRTH; SWEDISH (PEOPLE);

EID: 84993949422     PISSN: None     EISSN: 11782218     Source Type: Journal    
DOI: 10.4137/SART.S38887     Document Type: Article

References (45)

1. Gyarmathy VA, Giraudon I, Hedrich D, Montanari L, Guarita B, Wiessing L. Drug use and pregnancy -challenges for public health. Euro Surveill. 2009;14(9):33-6.
2. EMCDDA. European Drug Report 2015: Trends and Developments. Lisbon, Portugal: EMCDDA; 2015.
3. Selin J, Perälä R, Stenius K, Partanen A, Rosenqvist P, Alho H. Opioid substitution treatment in Finland and other Nordic countries: established treatment, varying practices. Nordic Stud Alcohol Drugs. 2015;32(2):311-24.
4. Bell J, Harvey-Dodds L. Pregnancy and injecting drug use. BMJ. 2008;336(7656):1303-5.
5. EMCDDA. Pregnancy, Childcare and the Family: Key Issues for Europe’s Response to Drugs. Lisbon, Portugal: EMCDDA; 2012.
6. Little M, Shah R, Vermeulen MJ, Gorman A, Dzendoletas D, Ray JG. Adverse perinatal outcomes associated with homelessness and substance use in pregnancy. CMAJ. 2005;173(6):615-8.
7. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic I. Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. Yonsei Med J. 2008;49(5):705-13.
8. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92(5):854-8.
9. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat. 2003;24(4):363-7.
10. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:CD006318.
11. Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis. 2010;29(2):175-91.
12. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070-6.
13. Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am. 2012;35(2):441-60.
14. Available at: http://www.emcdda.europa.eu/data/treatment-overviews/Sweden. Accessed November 15, 2015.
15. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1-10.
16. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275-81.
17. Gordon AL, Lopatko OV, Stacey H, et al. Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. J Addict Med. 2012;6(4):258-64.
18. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-31.
19. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96(1-2):69-78.
20. Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67(10):1053-9.
21. Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9(2):81-6.
22. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S; Groupe d’Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82(3):250-7.
23. Metz V, Jagsch R, Ebner N, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol. 2011;26(6):412-21.
24. Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127(1-3):200-6.
25. Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol. 2004;191(6):1885-97.
26. Norgaard M, Nielsson MS, Heide-Jorgensen U. Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study. Subst Abuse. 2015;9(suppl 2):5-11.
27. National Board of Health and Welfare. The Swedish Medical Birth Register -A Summary of Content and Quality. Stockholm: Centre for Epidemiology Swedish National Board of Health and Welfare; 2003.
28. Axelsson O. The Swedish medical birth register. Acta Obstet Gynecol Scand. 2003;82(6):491-2.
29. Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet. 2004;43(5):329-40.
30. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996;85(7):843-8.
31. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing [Computer Program]. Vienna, Austria: R Foundation for Statistical Computing; 2014.
32. epiR: Tools for the Analysis of Epidemiological Data. R Package Version 0.9-62. [Computer Program]. 2015.
33. Smith LK, Draper ES, Evans TA, et al. Associations between late and moderately preterm birth and smoking, alcohol, drug use and diet: a population-based case-cohort study. Arch Dis Child Fetal Neonatal Ed. 2015;100(6):F486-91.
34. Jones HE, Heil SH, Tuten M, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend. 2013;131(3):271-7.
35. Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2013;42(6):634-43.
36. Waldenstrom U, Aasheim V, Nilsen AB, Rasmussen S, Pettersson HJ, Schytt E. Adverse pregnancy outcomes related to advanced maternal age compared with smoking and being overweight. Obstet Gynecol. 2014;123(1):104-12.
37. Cleary BJ, Eogan M, O’Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107(8):1482-92.
38. Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol. 2003;24(3):195-221.
39. Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG. 2014;121(12):1471-81.
40. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279-88.
41. Miller A, Riehle-Colarusso T, Siffel C, Frias JL, Correa A. Maternal age and prevalence of isolated congenital heart defects in an urban area of the United States. Am J Med Genet A. 2011;155A(9):2137-45.
42. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction. 2004;99(2):209-14.
43. Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015;125(2):363-8.
44. Jernite M, Viville B, Escande B, Brettes JP, Messer J. [Buprenorphine and pregnancy. Analysis of 24 cases]. Arch Pediatr. 1999;6(11):1179-85.
45. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009;15(3):128-34.